Insmed (INSM)

William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Stifel raised the firm's price target on Insmed to $145 from $121 and keeps a Buy rating on the shares following FDA's recent approval of Brinsupri as the first approved therapy for treatment of non-C...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Off...

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

Insmed (INSM) came out with a quarterly loss of $1.7 per share versus the Zacks Consensus Estimate of a loss of $1.3. This compares to a loss of $1.94 per share a year ago.